Table 3.
Details of perioperative chemotherapy in patients who underwent perihepatic lymphadenectomy
| Without perihepatic lymph node metastases | With perihepatic lymph node metastases | |
|---|---|---|
| (n = 120) | (n = 54) | |
| Neoadjuvant chemotherapy | ||
| No | 12 (10·0) | 8 (15) |
| Yes | 108 (90·0) | 46 (85) |
| No. of cycles of chemotherapy* | 6 (3–30) | 6 (2–14) |
| Oxaliplatin-based | 90 of 108 (83·3) | 35 of 46 (76) |
| Irinotecan-based | 26 of 108 (24·1) | 15 of 46 (33) |
| Use of bevacizumab | 78 of 108 (72·2) | 32 of 46 (70) |
| Use of cetuximab/panitumumab | 12 of 108 (11·1) | 6 of 46 (13) |
| Adjuvant chemotherapy | ||
| Unknown | 5 | 4 |
| No | 33 of 115 (28·7) | 15 of 50 (30) |
| Yes | 82 of 115 (71·3) | 35 of 50 (70) |
| No. of cycles of chemotherapy* | 6 (1–12) | 6 (1–12) |
| Oxaliplatin-based | 57 of 78 (73) | 16 of 34 (47) |
| Irinotecan-based | 14 of 78 (18) | 11 of 34 (32) |
| Use of bevacizumab | 29 of 77 (38) | 13 of 34 (38) |
| Use of cetuximab/panitumumab | 9 of 77 (12) | 6 of 34 (18) |
Values in parentheses are percentages unless indicated otherwise;
*
values are median (range).